By admin 
In a move signaling a robust commitment to its next-generation immunotherapy pipeline, IN8bio has officially appointed Oxana Polyakova, a seasoned veteran in the field of oncology and cell therapy, as its new Senior Vice President of Research and Development. This strategic hire comes at a pivotal juncture for the clinical-stage biopharmaceutical company, which has been making significant strides in the development of innovative gamma-delta T cell therapies aimed at treating cancers with high unmet medical needs. Polyakova’s transition to IN8bio is not merely a lateral move within the biotech industry; it represents a consolidation of expertise in one of the most promising yet challenging frontiers of modern medicine: the use of unconventional T cells to breach the defenses of solid tumors and hematological malignancies.
Prior to joining the leadership team at IN8bio, Polyakova served as the Chief Scientific Officer at LAVA Therapeutics. During her tenure at LAVA, she was instrumental in advancing the company’s proprietary Gammabody platform, which focuses on developing bispecific gamma-delta T cell engagers. Her work there was characterized by a deep dive into the mechanics of how these unique immune cells can be redirected to recognize and eliminate tumor cells while sparing healthy tissue. The industry has watched closely as bispecific engagers and cell therapies have competed and collaborated for dominance in the immunotherapy landscape, and Polyakova’s move suggests a strategic pivot toward the cellular therapy side of the gamma-delta T cell equation. At IN8bio, she will be tasked with overseeing the research and development programs that underpin the company’s "DeltEx" platform, a technology designed to create chemotherapy-resistant gamma-delta T cells that can survive and thrive in the toxic microenvironment of a tumor undergoing standard-of-care treatment.
The appointment of Polyakova is a clear indicator that IN8bio is preparing for an intensified phase of clinical maturation. As the company moves its lead candidates, including INB-200 and INB-400, through various stages of clinical trials, the need for an R&D leader who understands both the granular science of immunology and the high-level strategy of drug development is paramount. INB-200, which focuses on newly diagnosed glioblastoma multiforme (GBM), represents a bold attempt to tackle one of the most aggressive and lethal forms of brain cancer. By utilizing autologous gamma-delta T cells that have been genetically modified to resist the effects of temozolomide, the standard chemotherapy for GBM, IN8bio is attempting to synchronize immunotherapy with traditional oncology protocols rather than positioning them as mutually exclusive options. Polyakova’s experience in navigating complex biological pathways will be essential as the company seeks to optimize these treatment regimens and demonstrate their efficacy to regulatory bodies.
The broader context of this hire reflects a "war for talent" within the biotechnology sector that has only intensified as we move through the mid-2020s. In the Pharmalot tradition of tracking the "comings and goings" of the industry’s brightest minds, Ed Silverman notes that the movement of a CSO from a prominent player like LAVA Therapeutics to a specialized firm like IN8bio often signals a shift in where the most groundbreaking research is occurring. Gamma-delta T cells have long been the "underdogs" of the T cell world, overshadowed by the more common alpha-beta T cells used in traditional CAR-T therapies. However, gamma-delta T cells offer several distinct advantages: they possess innate-like properties that allow them to recognize a wide array of antigens without the need for Major Histocompatibility Complex (MHC) presentation, and they are less likely to cause Graft-versus-Host Disease (GvHD), making them ideal candidates for "off-the-shelf" or allogeneic cell therapies.
Polyakova’s mandate at IN8bio will likely extend beyond the laboratory and into the realm of strategic clinical positioning. As the Senior Vice President of R&D, she will be a key voice in determining how the company allocates its resources across its diverse pipeline. This includes not only the autologous programs for GBM but also the allogeneic "off-the-shelf" programs aimed at leukemia and other liquid tumors. The challenge of scaling cell therapy remains one of the industry’s most significant hurdles. While autologous therapies—where a patient’s own cells are harvested, modified, and re-infused—have shown remarkable results, they are logistically complex and prohibitively expensive. Polyakova’s background in bispecifics, which are essentially "off-the-shelf" proteins, may provide IN8bio with fresh perspectives on how to streamline their cellular manufacturing processes and move closer to a more accessible and affordable model of care.
The economic and legislative landscape of 2026 also plays a crucial role in the backdrop of this appointment. With the ongoing implementation of the Inflation Reduction Act’s drug pricing provisions and the constant pressure from advocacy groups to increase access to life-saving medicines, biotech companies are under more pressure than ever to prove the value of their innovations. For a company like IN8bio, which is targeting diseases with limited treatment options and poor prognoses, the bar for clinical benefit is high, but so is the potential reward. Polyakova will need to lead an R&D organization that is not only scientifically rigorous but also attuned to the realities of the market. This means designing trials that produce clear, undeniable data on overall survival and quality of life—metrics that payers and providers are increasingly prioritizing.
Beyond the technical and strategic requirements of the role, the "all work and no play" sentiment mentioned in the original report hints at the human element of executive leadership in high-stakes biotech. The burnout rate in R&D is notoriously high, and the pressure to deliver results for investors while managing the hopes of patients can be overwhelming. Polyakova’s reputation as a leader who can maintain a high-performing team while navigating these pressures will be a significant asset for IN8bio. The company’s culture, which prides itself on being at the cutting edge of science, will likely be shaped by her vision of how research should be conducted in an era of rapid AI integration and high-throughput screening.
The competitive landscape for gamma-delta T cell therapies is also evolving. Companies like Adicet Bio and various academic spin-offs are also vying for dominance in this niche. By securing a leader of Polyakova’s caliber, IN8bio is making a statement to its competitors and the investment community that it intended to lead the pack. Her deep understanding of the Gammabody platform at LAVA provides her with a unique "competitor’s eye view" of the field, allowing her to identify the strengths and weaknesses of different approaches to gamma-delta T cell activation. Whether it is through direct cell infusion or the use of engagers, the ultimate goal remains the same: to turn the immune system into a precise and powerful weapon against cancer.
Looking forward, the industry will be watching for the first major data readouts under Polyakova’s leadership. If IN8bio can successfully demonstrate that its chemotherapy-resistant T cells can significantly extend the lives of GBM patients, it would be a landmark achievement in oncology. Glioblastoma has been a "graveyard" for many promising drugs over the last few decades, and a win here would validate the entire DeltEx platform. Polyakova’s role in refining the protocols for these trials and ensuring that the underlying science is airtight cannot be overstated. She will be responsible for bridging the gap between early-stage discovery and late-stage clinical development, a transition that often defines the success or failure of a biotech firm.
In the afternoon Pharmalot updates and the morning Pharmalittle newsletters, the narrative of leadership changes often serves as a shorthand for the health and direction of the industry. The move of Oxana Polyakova to IN8bio is a story of a scientist-leader seeking a new platform to solve old problems. It reflects a broader trend of "immune-convergence," where different modalities—cell therapy, bispecifics, and traditional chemotherapy—are being integrated into a singular, more effective strategy. As she settles into her role as SVP of R&D, the focus will remain on the patients waiting for a breakthrough. For those suffering from glioblastoma or refractory leukemia, the news of a seasoned expert taking the helm of a promising R&D department is more than just a corporate announcement; it is a signal of continued hope in the pursuit of a cure.
As the industry gathers at conferences and investors pore over quarterly reports in the coming months, the name Oxana Polyakova will undoubtedly be linked to the progress of IN8bio. Her appointment is a reminder that in the world of drug development, the most valuable asset is often the human expertise that can navigate the labyrinth of biology and regulation. With her at the R&D helm, IN8bio is well-positioned to continue its mission of redefining the boundaries of what is possible in cancer treatment, ensuring that the "coming and going" of industry leaders continues to drive the innovation that the medical community so desperately requires. Through the lens of Ed Silverman’s reporting, we see a sector that is constantly reinventing itself, driven by individuals who are willing to take on the hardest challenges in medicine. Polyakova’s journey from LAVA to IN8bio is just the latest chapter in that ongoing saga of scientific discovery and corporate strategy.
